Combining chemotherapy with ICB can be used to extend a synergistic therapeutic effect.317,318 A pooled analysis of three randomized clinical trials indicated that among patients with PD-L1-negative advanced / metastatic NSCLC, efficacy is better with pembrolizumab plus chemotherapy compared with chemotherapy alone.319 Similar results were obtained in PD-L1-positive NSCLC patients. Here, CD274 is linked to non-small cell lung carcinoma.